Clinical trial on Augmentin against acute exacerbation of chronic bronchitis (AECB) in adults

ZHUO Chao; et al

您当前的位置：

首页 >

文章列表页 >

Clinical trial on Augmentin against acute exacerbation of chronic bronchitis (AECB) in adults

更新时间：2024-01-17

- Clinical trial on Augmentin against acute exacerbation of chronic bronchitis (AECB) in adults
- Journal of Chongqing Medical University Issue 3, Pages: 339-341(2002)
- 作者机构：
  
  1. 重庆医科大学临床学院感染科
  2. 重庆水轮机械厂职工医院,重庆,400016
  3. ,重庆,400063
- 作者简介：
- 基金信息：
- DOI：
  CLC： R562.21
- Published：2002，
扫描看全文
[1]卓超,肖永红,罗勤东.力百汀新剂型治疗慢性支气管炎急性发作的临床研究[J].重庆医科大学学报,2002(03):339-341.

ZHUO Chao, et al. Clinical trial on Augmentin against acute exacerbation of chronic bronchitis (AECB) in adults. [J]. Journal of Chongqing Medical University (3):339-341(2002)
[1]卓超,肖永红,罗勤东.力百汀新剂型治疗慢性支气管炎急性发作的临床研究[J].重庆医科大学学报,2002(03):339-341. DOI：

ZHUO Chao, et al. Clinical trial on Augmentin against acute exacerbation of chronic bronchitis (AECB) in adults. [J]. Journal of Chongqing Medical University (3):339-341(2002) DOI：

摘要

目的:以力百汀（阿莫西林克拉维酸）新剂型为试验药

头孢呋辛、头孢克洛为对照药

力百汀通过/500/125mg两次口服给药

治疗成年人慢性支气管炎急性发作

评价前者的临床安全性和有效性。方法:随机、单盲、平行法对照研究。结果:三组各完成合格病例例

力百汀组、头孢呋辛组及头孢克洛组的临床有效率分别为、及

细1291.7%83.3%91.7%菌清除率分别为、及

不良反应发生率为、和

三组比较

临床有效率及细菌清除率均无显著性差100%90%71.4%8.3%00异。结论:力百汀新剂型两次口服给药

能安全有效地用于治疗成年慢性支气管炎急性发作。500/125mg

Abstract

Objective:The safty and efficacy of Augmentin (amoxicillin/clavulanic acid 500/125mg) was evaluated through clinical study in treating acute exacerbation of chronic bronchitis. Methods: A randomized-controlled clinical trial on Augmentin

cefuroxime and cefaclor against AECB was designed

Thirty-six patients were enrolled

who were divided into three groups

and each group included twelve patients. Augmentin 625mg Bid×××7d; cefuroxime 250mg Bid7d; cefaclor 250mg Tid7d. Results: The clinical effective rates of augmentin was 91.7%

compared with 83.7% of cefuroxime and 91.7% of cefaclor. The bacterial eradication rate was similar among three groups. Incidence of adverse reactions was 8.3% (1/12) in Augmentin group. Conclusion: The efficacy and safty of Augmentin in treating AECB was reliable.

关键词

力百汀慢性支气管炎急性发作

Keywords

AugmentinAECB

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical trial on gatifloxacin against acute exacerbation ofchronic bronchitis (AECB) in adults

Related Author

ZENG Aizhong

et al

罗勤东

肖永红

李崇智

Related Institution

重庆水轮机厂职工医院

北京大学临床药理研究所

重庆医科大学临床学院感染科

⁰